-
FACTORS ASSOCIATED WITH LONGITUDINAL TRAJECTORIES OF HYDROXYUREA ADHERENCE AMONG INDIVIDUALS WITH SICKLE CELL DISEASE: A GROUP-BASED TRAJECTORY MODELING STUDY
Mar 18, 2026, 21:38 PM -
HEALTHCARE RESOURCE UTILIZATION AND COSTS IN MEN WITH PROSTATE CANCER TREATED WITH ANDROGEN DEPRIVATION THERAPY USING REAL-WORLD DATA
Mar 18, 2026, 21:38 PM -
AUTOMATING BRIEFING BOOK DEVELOPMENT FOR NICE HEALTH TECHNOLOGY ASSESSMENT SUBMISSIONS USING GENERATIVE AI
Mar 18, 2026, 21:38 PM -
GUIDING RECORD LINKAGE METHOD (RL) SELECTION IN HEOR: A TARGETED REVIEW AND STRUCTURED DECISION FRAMEWORK
Mar 18, 2026, 21:38 PM -
CHARACTERIZING AGE-RELATED PATTERNS IN HEALTHCARE COSTS AND UTILIZATION AMONG PEOPLE LIVING WITH ANGELMAN SYNDROME IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
CHOOSING FOR THE WORSE-OFF: A STRUCTURAL SOCIAL WELFARE MODEL OF EQUITY-EFFICIENCY PREFERENCES IN TYPE 2 DIABETES TREATMENT CHOICES
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF NEOADJUVANT AND ADJUVANT PEMBROLIZUMAB IN LOCALLY ADVANCED HEAD AND NECK CANCER
Mar 18, 2026, 21:38 PM -
CLINICAL CHARACTERISTICS, BIOMARKER USE, AND PATIENT-REPORTED BURDEN IN PLATINUM-RESISTANT OVARIAN CANCER (PROC) IN CLINICAL PRACTICE
Mar 18, 2026, 21:38 PM -
INDIRECT TREATMENT COMPARISON OF TEPROTUMUMAB VS RITUXIMAB OR TOCILIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS AND BUDGET IMPACT OF CAFFEINE CITRATE VERSUS AMINOPHYLLINE FOR APNEA OF PREMATURITY ACROSS A PUBLIC HEALTHCARE SYSTEM IN MEXICO
Mar 18, 2026, 21:38 PM -
THE IMPACT OF DIFFERENT TIME-VARYING NETWORK META-ANALYSIS METHODS TO ASSESS TALAZOPARIB + ENZALUTAMIDE VERSUS OLAPARIB + ABIRATERONE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Mar 18, 2026, 21:38 PM -
EQ-5D BASED UTILITY VALUES BY CLINICAL RESPONSE AND SYMPTOM SEVERITY IN JAPANESE PATIENTS WITH MAJOR DEPRESSIVE DISORDER: POST-HOC ANALYSIS OF JAPANESE BREXPIPRAZOLE CLINICAL TRIALS
Mar 18, 2026, 21:38 PM -
COST PER CLINICAL WEIGHT-LOSS GOAL ACHIEVEMENT WITH SEMAGLUTIDE 2.4 MG VERSUS LIRAGLUTIDE 3 MG FROM A COLOMBIAN INSURER PERSPECTIVE
Mar 18, 2026, 21:38 PM -
ASSESSING THE UTILIZATION OF EARLY ACCESS PATHWAYS AND IMPLEMENTATION OF TIME-LIMITED REIMBURSEMENT AND TEMPORARY ACCESS PROCESS IN CANADA
Mar 18, 2026, 21:38 PM -
BUDGET IMPACT AND COST CALCULATOR MODEL FOR POHERDY® (PERTUZUMAB-DPZB) IN THE TREATMENT OF HER2-POSITIVE BREAST CANCER
Mar 18, 2026, 21:38 PM -
DYNAMIC BUDGET IMPACT OF ARTIFICIAL INTELLIGENCE (AI)-ASSISTED IMAGING INTERPRETATION FOR BRAIN METASTASES IN ADVANCED LUNG CANCER
Mar 18, 2026, 21:38 PM -
CAN LINKED CLAIMS-EHR DATA BE USED TO GENERATE SYNTHETIC DATA? AN EVALUATION OF THE MARKETSCAN-VERADIGM LINKED CLAIMS + EHR DATABASE
Mar 18, 2026, 21:38 PM -
REAL-WORLD DATA ANALYSIS OF ONCOLOGICAL DRUG FUNDING AND ACCESS HETEROGENEITY IN THE BRAZILIAN PUBLIC HEALTH SYSTEM (SUS)
Mar 18, 2026, 21:38 PM -
VALIDATION OF A CLAIMS ALGORITHM TO IDENTIFY PATIENTS WITH MYOTONIC DYSTROPHY TYPE 1 (DM1)
Mar 18, 2026, 21:38 PM -
ESTABLISHING VALIDITY AND DEVELOPING A PREDICTOR TOOL FOR ESTIMATION OF WILLINGNESS TO PAY BASED THRESHOLD FOR INDIA
Mar 18, 2026, 21:38 PM
